Akums Drugs and Pharmaceuticals Ltd

Thu 27/08/2026,15:55:27 | NSE : AKUMS

₹761.20-4.90 (-0.64%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 769.00

Previous Close

₹ 766.10

Volume

359949

Mkt Cap ( ₹ Cr)

₹ 11980.83

High

₹ 778.05

Low

₹ 760.00

52 Week High

₹ 783.00

52 Week Low

₹ 409.30

Book Value Per Share

₹ 216.98

Dividend Yield

0.39

Face Value

₹ 2.00

What's Your Call?

Collective community sentiment on Akums Drugs and Pharmaceuticals Ltd

Your Vote -

Buy

76.32%

Hold

13.16%

Sell

10.53%

76.32%

38 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

100%

Sell Order Quantity

0%

Bid Price

Qty

761.20

39

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

39

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Option Chain

Analyzes market sentiment, predicts Akums Drugs and Pharmaceuticals Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Akums Drugs&Pharma. - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    25 Aug 2026, 4:51PM Intimation of Schedule of the Investors/Analysts Meet
  • Akums Drugs&Pharma. - Analysts/Institutional Investor Meet/Con. Call Updates

    25 Aug 2026, 4:43PM Akums Drugs and Pharmaceuticals Limited has informed the Exchange about Schedule of meet
  • Akums Drugs&Pharma. - Analysts/Institutional Investor Meet/Con. Call Updates

    24 Aug 2026, 3:03PM Akums Drugs and Pharmaceuticals Limited has informed the Exchange about an Update on schedule of the Investors/ Analysts Meet to be held on August 25,
  • Akums Drugs&Pharma. - Update On Schedule Of The Investors/Analysts Meet To Be Held On August 25, 2026

    24 Aug 2026, 3:09PM Akums Drugs and Pharmaceuticals Limited has informed the exchange about an update on schedule of the Investors/ Analysts Meet to be held on August 25,
  • Akums Drugs&Pharma. Q1 net profit down 0.07% at Rs 44.84 cr

    22 Aug 2026, 7:50PM The company reported standalone net profit of Rs 44.84 crore for the quarter ended June 30, 2026 as compared to Rs 44.87 crore in the same period last
  • Akums Drugs&Pharma. - Analysts/Institutional Investor Meet/Con. Call Updates

    13 Aug 2026, 3:08PM Akums Drugs and Pharmaceuticals Limited has informed the Exchange about Schedule of meet
  • Akums Drugs&Pharma. - Analysts/Institutional Investor Meet/Con. Call Updates

    13 Aug 2026, 2:41PM Akums Drugs and Pharmaceuticals Limited has informed the Exchange about Transcript
  • Akums Drugs&Pharma. - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    13 Aug 2026, 3:06PM Intimation of Schedule of the Investors/Analysts Meet
  • Akums Drugs&Pharma. - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

    13 Aug 2026, 2:49PM Transcript of Investors/Analysts conference call for the unaudited financial results of Q1 FY 27
  • Akums Drugs&Pharma. - Analysts/Institutional Investor Meet/Con. Call Updates

    10 Aug 2026, 5:18PM Akums Drugs and Pharmaceuticals Limited has informed the Exchange about Schedule of meet
  • Akums Drugs&Pharma. - Analysts/Institutional Investor Meet/Con. Call Updates

    10 Aug 2026, 3:46PM Akums Drugs and Pharmaceuticals Limited has informed the Exchange about Link of Recording
  • Akums Drugs&Pharma. - Copy of Newspaper Publication

    10 Aug 2026, 3:10PM Copy of Newspaper Publication
  • Akums Drugs&Pharma. - Monitoring Agency Report

    10 Aug 2026, 3:00PM Monitoring Agency Report for the quarter ended June 30, 2026
  • Akums Drugs&Pharma. - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    10 Aug 2026, 5:16PM Intimation of Schedule of the Investors/Analysts Meet to be held on August 14, 2026
  • Akums Drugs&Pharma. - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

    10 Aug 2026, 3:43PM Link of audio recording of Investors/Analysts Conference Call
  • Akums Drugs&Pharma. - Newspaper Publication

    10 Aug 2026, 3:08PM Newspaper Publication
  • Akums Drugs&Pharma. - Monitoring Agency Report

    10 Aug 2026, 2:58PM Monitoring Agency Report for the quarter ended June 30, 2026
  • Akums Drugs&Pharma. - Analysts/Institutional Investor Meet/Con. Call Updates

    8 Aug 2026, 5:17PM Akums Drugs and Pharmaceuticals Limited has informed the Exchange about Presentation
  • Akums Drugs&Pharma. - Press Release

    8 Aug 2026, 5:01PM Akums Drugs and Pharmaceuticals Limited has informed the Exchange regarding a press release dated August 08, 2026, titled ""Press Release"".
  • Akums Drugs&Pharma. - Updates

    8 Aug 2026, 4:14PM Akums Drugs and Pharmaceuticals Limited has informed the Exchange regarding 'Un-audited Financial Results for the Quarter ended 30th June, 2026'.
  • Akums Drugs&Pharma. - Outcome of Board Meeting

    8 Aug 2026, 3:46PM Akums Drugs and Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
  • Akums Drugs&Pharma. - Announcement under Regulation 30 (LODR)-Investor Presentation

    8 Aug 2026, 5:15PM Investor Presentation
  • Akums Drugs&Pharma. - Press Release

    8 Aug 2026, 5:07PM Press Release
  • Akums Drugs&Pharma. - Un-Audited Financial Results For The Quarter Ended 30Th June, 2026

    8 Aug 2026, 4:00PM Un-audited Financial Results for the Quarter ended 30th June, 2026
  • Akums Drugs&Pharma. - Board Meeting Outcome for Un-Audited Financial Results For The Quarter Ended 30Th June, 2026

    8 Aug 2026, 3:52PM Un-audited Financial Results for the Quarter ended 30th June, 2026
  • Akums Drugs&Pharma. - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    5 Aug 2026, 7:42PM Intimation of schedule of the Analysts/ Investor Conference Call (Group Meet) for un-audited financial results of Q1 FY27
  • Akums Drugs&Pharma. - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    5 Aug 2026, 7:39PM Intimation of schedule of the Analysts/ Investor Conference Call (Group Meet) for un-audited financial results of Q1 FY27
  • Akums Drugs&Pharma. - Analysts/Institutional Investor Meet/Con. Call Updates

    5 Aug 2026, 7:05PM Akums Drugs and Pharmaceuticals Limited has informed the Exchange about Schedule of meet
  • Akums Drugs&Pharma. - Board Meeting Intimation for Un-Audited (Standalone & Consolidated) Financial Results For The Quarter E

    5 Aug 2026, 6:46PM Akums Drugs And Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/08/2026 ,inter alia,
  • Akums Drugs&Pharma. - Announcement under Regulation 30 (LODR)-Acquisition

    23 Jul 2026, 11:20PM Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015- Acquisition of Oriflame India's Manufa
  • Akums Drugs&Pharma. - General Updates

    23 Jul 2026, 11:15PM Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Acquisition of Oriflame India s Manuf
  • Akums Drugs&Pharma. has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2026

    18 Jul 2026, 7:20PM As of June 2026, 75.26% is owned by Indian Promoters, 22.01% by Public and 2.73% by Non Promoters-Non Public. <p align=justify> Institutional holds 15
  • Akums Drugs&Pharma. - Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    11 Jul 2026, 6:28PM Voting Results and Scrutinizer's Report of the 22nd Annual General Meeting
  • Akums Drugs&Pharma. - Shareholders meeting

    11 Jul 2026, 6:23PM Akums Drugs and Pharmaceuticals Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on July 10, 2026. Further
  • Akums Drugs&Pharma. - Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    11 Jul 2026, 6:28PM Voting Results and Scrutinizer's Report of the 22nd Annual General Meeting
  • Akums Drugs&Pharma. - Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    11 Jul 2026, 6:28PM Voting Results and Scrutinizer's Report of the 22nd Annual General Meeting
  • Akums Drugs&Pharma. - Shareholder Meeting / Postal Ballot-Outcome of AGM

    10 Jul 2026, 6:21PM Proceedings of the 22nd Annual General Meeting of the Company
  • Akums Drugs&Pharma. - Shareholders meeting

    10 Jul 2026, 6:16PM Akums Drugs and Pharmaceuticals Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on July 10, 2026
  • Akums Drugs&Pharma. - Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    11 Jul 2026, 6:28PM Voting Results and Scrutinizer's Report of the 22nd Annual General Meeting
  • Akums Drugs&Pharma. - Certificate under SEBI (Depositories and Participants) Regulations, 2018

    8 Jul 2026, 4:01PM Certificate pursuant to Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018
  • Akums Drugs&Pharma. - Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    11 Jul 2026, 6:28PM Voting Results and Scrutinizer's Report of the 22nd Annual General Meeting
  • Akums Drugs&Pharma. - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    8 Jul 2026, 4:04PM Certificate pursuant to Regulation 74 (5) of the SEBI (Depositories and Participants) Regulations, 2018
  • Akums Drugs&Pharma. - Update On Penalty Imposed By The Deputy Commissioner Of State Tax, Gujarat, On Maxcure Nutravedics Limi

    4 Jul 2026, 6:04PM Update on penalty imposed by the Deputy Commissioner of State Tax, Gujarat, on Maxcure Nutravedics Limited, wholly owned subsidiary of the Company
  • Akums Drugs&Pharma. - Action(s) taken or orders passed

    4 Jul 2026, 6:00PM Update on penalty imposed by the Deputy Commissioner of State Tax, Gujarat, on Maxcure Nutravedics Limited, wholly owned subsidiary of the Company
  • Akums Drugs&Pharma. - Trading Window

    25 Jun 2026, 1:10PM Akums Drugs and Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Tradin
  • Akums Drugs&Pharma. - Copy of Newspaper Publication

    19 Jun 2026, 11:39AM Newspaper Advertisements of the 22nd Annual General Meeting of the Company
  • Akums Drugs&Pharma. - Notice And Integrated Annual Report For The Financial Year 2025-26 To Those Members Who Have Not Regist

    19 Jun 2026, 10:56AM Notice and Integrated Annual Report for the Financial Year 2025-26 to those members who have not registered their e-mail ID's
  • Akums Drugs&Pharma. - Updates

    19 Jun 2026, 10:53AM Akums Drugs and Pharmaceuticals Limited has informed the Exchange regarding 'Notice and Integrated Annual Report for the Financial Year 2025-26 to tho
  • Akums Drugs&Pharma. - Business Responsibility and Sustainability Reporting (BRSR)

    18 Jun 2026, 6:28PM Business Responsibility and Sustainability Reporting for the FY 2025-26
  • Akums Drugs&Pharma. - Updates

    18 Jun 2026, 6:23PM Akums Drugs and Pharmaceuticals Limited has informed the Exchange regarding 'Business Responsibility and Sustainability Report for the Financial Year
  • Akums Drugs&Pharma. - Reg. 34 (1) Annual Report.

    18 Jun 2026, 6:00PM Integrated Annual Report for the FY 2025-26
  • Akums Drugs&Pharma. - Shareholders meeting

    18 Jun 2026, 5:27PM Akums Drugs and Pharmaceuticals Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on July 10, 2026
  • Akums Drugs&Pharma. - Notice Of The 22Nd Annual General Meeting

    18 Jun 2026, 5:33PM Notice of the 22nd Annual General Meeting
  • Akums Drugs&Pharma. - General Updates

    16 Jun 2026, 11:18AM Newspaper Advertisement- Information regarding 22nd AGM and Final & Special Dividend
  • Akums Drugs&Pharma. - Analysts/Institutional Investor Meet/Con. Call Updates

    10 Jun 2026, 2:39PM Intimation of Schedule of the investor/analysts meets
  • Akums Drugs&Pharma. - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    10 Jun 2026, 2:40PM Intimation of Schedule of the investor/analysts meets
  • Akums Drugs&Pharma. - Analysts/Institutional Investor Meet/Con. Call Updates

    9 Jun 2026, 2:23PM Akums Drugs and Pharmaceuticals Limited has informed the Exchange about Schedule of meet
  • Akums Drugs&Pharma. - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    9 Jun 2026, 2:31PM Intimation of Schedule of the Investor/Analyst Meet
  • Akums Drugs&Pharma. has declared 50% Final dividend for the financial year March 2026

    7 Jun 2026, 1:20PM Akums Drugs & Pharmaceuticals Ltd. on Friday, 15 May 2026, has announced Final dividend of 50 percent on Equity Share, to its shareholders holding sha
  • Akums Drugs&Pharma. - Analysts/Institutional Investor Meet/Con. Call Updates

    3 Jun 2026, 7:03PM Intimation of Schedule of the Investor/Analysts Meet
  • Akums Drugs&Pharma. - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    3 Jun 2026, 6:42PM Intimation of Schedule of the Investor/Analysts Meet
  • Akums Drugs&Pharma. - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    28 May 2026, 6:28PM Intimation of Schedule of the Investor/Analysts Conference Call (group meet)
  • Akums Drugs&Pharma. - Analysts/Institutional Investor Meet/Con. Call Updates

    28 May 2026, 6:25PM Akums Drugs and Pharmaceuticals Limited has informed the Exchange about Schedule of meet

Key fundamentals

Evaluate the intrinsic value of Akums Drugs and Pharmaceuticals Ltd stock 

Name March-26 March-25 March-24
Assets 2441.119 2309.177 370.164
Liabilities 2441.119 2309.177 370.164
Equity 30.621 30.621 28.613
Gross Profit 97.46 138.499 -126.658
Net Profit 111.64 160.998 -165.451
Cash From Operating Activities -2.147 91.002 247.907
NPM(%) 8.27 12.27 -11.45
Revenue 1348.736 1311.784 1444.119
Expenses 1251.276 1173.285 1570.777
ROE(%) 3.26 4.71 -4.84

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day
03 Jul 2026 1 50 0.39 516.95

Peers

Other companies within the same industry or sector that are comparable to Akums Drugs and Pharmaceuticals Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 890.25 2.36 22.52 437.11 -26.19 0.56
Lotus Eye Hospital and Institute Ltd 112.63 0.91 1609.00 1592.79 0.39 0.00
Vaishali Pharma Ltd 8.33 1.96 26.03 9992.09 15.42 0.00
Astec Lifesciences Ltd 585.90 -1.28 0.00 1706.59 -363.14 0.00

Company Info

Our Company was incorporated as a public limited company under the Companies Act, 1956 as `Akums Drugs and Pharmaceuticals Limited', pursuant to a certificate of incorporation dated April 19, 2004 issued by the RoC. Our Company received a certificate for commencement of business issued by the RoC dated May 13, 2004.Major Events and Milestones:2004-Incorporation of the Company-Established first plant for oral dosage commissioned at 19, 20, 21, sector 6A, Haridwar, Uttarakhand2007-Established dedicated manufacturing site for oral liquid dosage at 22, Sector 6A, Sidcul, Haridwar, Uttarakhand and sterile products at 2,3,4,5, Sector 6B, SIDCUL, Haridwar, Uttarakhand2009-Incorporated Maxcure Nutravedics Limited to venture into nutraceuticals2010-Dedicated a facility for hormones at 48, Sector 6A, SIDCUL, Haridwar, Uttarakhand-Dedicated a facility for cosmetics and dermatology at 47, Sector 6A, SIDCUL, Haridwar, Uttarakhand-Incorporated Akumentis Healthcare Limited to venture into branded formulations2011-Innovated bi-layered sustained release tablets for the first time2012-Acquired Pure and Cure Healthcare Private Limited to expand capacity and capabilities2013-Innovated tablet-in-tablet sustained release tablets for the first time-Acquired Malik Lifesciences Private Limited manufacturing sites to expand capacity and capabilities-Expanded into the African market2015-Expanded into the Asian market-Established research and development laboratory in Mumbai, Maharashtra to venture into regulated market2016-Maxcure Nutravedics Limited received US-NSF certification2019-Investment by Ruby QC Investment Holdings Pte. Ltd. in our Company to become a minority shareholder2021-Acquired Parabolic Drugs to form Akums Lifesciences Limited and ventured into APIs-Acquisition of a facility at Kotdwar, Uttarakhand by Akums Healthcare Limited2022-Plant at 19, 20, 21, Sector 6A, SIDCUL, Haridwar, Uttarakhand and plant at 2, 3, 4,5, Sector 6B, SIDCUL, Haridwar, Uttarakhand accredited European Union-Good Manufacturing Practices, qualifying for exports to European markets-Acquisition of a facility in Haridwar, Uttarakhand by Akums Healthcare Limited and a facility in Baddi, Himachal Pradesh by Pure and Cure Healthcare Private Limited2023-Acquisition of another facility in Baddi, Himachal Pradesh by Pure and Cure Healthcare Private Limited-Merger of Akums Lifesciences Limited with Pure and Cure Healthcare Private Limited 2024 -The Company has informed to exchange regarding new product launches.

Our Company was incorporated as a public limited company under the Companies Act, 1956 as `Akums Drugs and Pharmaceuticals Limited', pursuant to a certificate of incorporation dated April 19, 2004 issued by the RoC. Our Company received a certificate for commencement of business issued by the RoC dated May 13, 2004.Major Events and Milestones:2004-Incorporation of the Company-Established first plant for oral dosage commissioned at 19, 20, 21, sector 6A, Haridwar, Uttarakhand2007-Established dedicated manufacturing site for oral liquid dosage at 22, Sector 6A, Sidcul, Haridwar, Uttarakhand and sterile products at 2,3,4,5, Sector 6B, SIDCUL, Haridwar, Uttarakhand2009-Incorporated Maxcure Nutravedics Limited to venture into nutraceuticals2010-Dedicated a facility for hormones at 48, Sector 6A, SIDCUL, Haridwar, Uttarakhand-Dedicated a facility for cosmetics and dermatology at 47, Sector 6A, SIDCUL, Haridwar, Uttarakhand-Incorporated Akumentis Healthcare Limited to venture into branded formulations2011-Innovated bi-layered sustained release tablets for the first time2012-Acquired Pure and Cure Healthcare Private Limited to expand capacity and capabilities2013-Innovated tablet-in-tablet sustained release tablets for the first time-Acquired Malik Lifesciences Private Limited manufacturing sites to expand capacity and capabilities-Expanded into the African market2015-Expanded into the Asian market-Established research and development laboratory in Mumbai, Maharashtra to venture into regulated market2016-Maxcure Nutravedics Limited received US-NSF certification2019-Investment by Ruby QC Investment Holdings Pte. Ltd. in our Company to become a minority shareholder2021-Acquired Parabolic Drugs to form Akums Lifesciences Limited and ventured into APIs-Acquisition of a facility at Kotdwar, Uttarakhand by Akums Healthcare Limited2022-Plant at 19, 20, 21, Sector 6A, SIDCUL, Haridwar, Uttarakhand and plant at 2, 3, 4,5, Sector 6B, SIDCUL, Haridwar, Uttarakhand accredited European Union-Good Manufacturing Practices, qualifying for exports to European markets-Acquisition of a facility in Haridwar, Uttarakhand by Akums Healthcare Limited and a facility in Baddi, Himachal Pradesh by Pure and Cure Healthcare Private Limited2023-Acquisition of another facility in Baddi, Himachal Pradesh by Pure and Cure Healthcare Private Limited-Merger of Akums Lifesciences Limited with Pure and Cure Healthcare Private Limited 2024 -The Company has informed to exchange regarding new product launches.

Parent Organisation

Akums Drugs & Pharmaceuticals Ltd.

Founded

19/04/2004

Managing Director

Mr.Sanjeev Jain

NSE Symbol

AKUMSEQ

FAQ